Clinical trials: Gastro-intestinal Stromal Tumors
- Condition Gastro-intestinal Stromal Tumors
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
GIST
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with…
- Trial name
- NCT03465722
- Testing
- avapritinib, regorafenib
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 476 people
- Sponsor
- Blueprint Medicines Corporation
Gastrointestinal Stromal Tumors
A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
The primary objective of this trial is to evaluate the progress free survival (PFS) of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have progressed with prior anticancer therapies based on independent…
- Trial name
- NCT04282980
- Testing
- DCC-2618
- Where
- 9 sites in China
- Volunteers
- 39 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Gastrointestinal Stromal Tumor
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
A study to assess the safety and efficacy of SU11248 in patients with gastrointestinal stromal tumor (GIST) whose disease has failed imatinib therapy or who were intolerant to imatinib treatment.
- Trial name
- NCT00075218
- Testing
- SU011248
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 361 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumors
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Children and young adults with gastrointestinal stromal tumors (GIST) will be treated with sunitinib. The safety (including pharmacokinetics) and tolerability of sunitinib will be studied in these patients.
- Trial name
- NCT01396148
- Testing
- sunitinib malate dose escalation, sunitinib malate
- Where
- 9 sites in United States, Czechia and 1 more
- Volunteers
- 6 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumors
Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)
A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors…
- Trial name
- GRID (NCT01271712)
- Testing
- Regorafenib (Stivarga, BAY73-4506), Best supportive care
- Where
- 57 sites in United States, Austria and 15 more
- Volunteers
- 199 people
- Sponsor
- Bayer
Gastrointestinal Stromal Tumors
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
The purpose of this multicenter, single-arm, phase II trial is to evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).
- Trial name
- NCT00756509
- Testing
- Nilotinib
- Where
- 10 sites in Finland, France and 3 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors
DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)
This study will assess the safety, efficacy, and pharmacokinetics of DS-6157a in participants with advanced gastrointestinal stromal tumors (GIST).
- Trial name
- NCT04276415
- Testing
- DS-6157a
- Where
- 5 sites in United States, Japan
- Volunteers
- 34 people
- Sponsor
- Daiichi Sankyo
Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)
A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene
In the core study, participants with unresectable or metastatic gastrointestinal stromal tumors expressing c-kit were treated with either 400 mg or 600 mg imatinib mesylate for 3 years.
- Trial name
- NCT00237185
- Testing
- Imatinib mesylate
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Stromal Tumor(GIST)
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
the primary objective of this study is to assess the efficacy (progression-free survival,PFS) of DCC-2618 (ripretinib, ZL-2307) and sunitinib in patients with advanced gastrointestinal stromal tumors after treatment with…
- Trial name
- NCT04633122
- Testing
- Ripretinib, Sunitinib
- Where
- 18 sites in China
- Volunteers
- 108 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Gastrointestinal Stromal Tumors
Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies
This is a 2-arm, randomized, placebo-controlled, double-blind, international, multicenter study comparing the efficacy of ripretinib (DCC-2618) to placebo in patients who have received treatment with prior anticancer therapies.
- Trial name
- INVICTUS (NCT03353753)
- Testing
- DCC-2618
- Where
- 35 sites in United States, Australia and 11 more
- Volunteers
- 129 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Gastrointestinal Stromal Tumors
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
To monitor use in real practice including adverse events and efficacy on Sutent capsules (Sunitinib malate)
- Trial name
- NCT00444795
- Testing
- Sunitinib malate
- Where
- 47 sites in South Korea
- Volunteers
- 520 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumors
Study for Patients Previously Treated in Avapritinib Clinical Trials
This is an open-label extension study to provide long term safety data for GIST patients who are deriving clinical benefit from avapritinib upon the completion of avapritinib clinical trials.
- Trial name
- NCT04825574
- Testing
- Avapritinib
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Blueprint Medicines Corporation
Gastrointestinal Stromal Tumor (GIST)
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
This is a Phase II, non-randomized, open-label, multi-center study conducted in the USA. The purpose of this trial is to evaluate the use of long term adjuvant imatinib mesylate in patients at significant risk for recurrence…
- Trial name
- NCT00867113
- Testing
- imatinib mesylate
- Where
- 21 sites in United States
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Gastrointestinal Stromal Tumor (GIST)
A Study of Nilotinib Versus Imatinib in GIST Patients
This study will evaluate efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).
- Trial name
- ENESTg1 (NCT00785785)
- Testing
- Nilotinib (AMN107), imatinib (STI571)
- Where
- 165 sites in United States, Argentina and 33 more
- Volunteers
- 644 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors
Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT00716820
- Testing
- SUNITINIB MALATE
- Volunteers
- 472 people
- Sponsor
- Pfizer
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Cancer
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
This was a Phase II, open-label, non-randomized, multi-center study of oral dabrafenib in combination with oral trametinib in subjects with rare cancers harboring the BRAF V600E mutation including anaplastic thyroid cancer (ATC)…
- Trial name
- NCT02034110
- Testing
- Dabrafenib, Trametinib
- Where
- 41 sites in United States, Austria and 12 more
- Volunteers
- 206 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors
Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
This study will evaluate the preliminary efficacy of nilotinib in pretreated patients (Imatinib, Sunitinib) with unresectable or metastatic gastrointestinal stromal tumors.
- Trial name
- NCT01289028
- Testing
- Nilotinib
- Where
- 19 sites in Germany, Italy
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors
Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg
The study will investigate the comparative efficacy and safety of two oral inhibitors of Kit and PDGFR: nilotinib 400 mg bid, a novel agent, and imatinib 400 mg bid, an approved agent with an established efficacy.
- Trial name
- MACS0375 (NCT00751036)
- Testing
- Nilotinib, Imatinib
- Where
- 32 sites in Argentina, Brazil and 7 more
- Volunteers
- 94 people
- Sponsor
- Novartis Pharmaceuticals